Pain Medicine

A patient in stable recovery from opioid use disorder needs a routine gallbladder operation. The disagreement isn't whether his recovery matters — everyone agrees it does — it's whether protecting it means leaving his daily buprenorphine exactly as it is, or making room around it for the pain a real operation will cause.

A woman who has been stable for years on a high daily opioid dose is being pushed toward a fast taper by a policy that was never meant to require one. The disagreement is about pace, not destination — everyone in the room already agrees the dose is higher than anyone would start her on today.

A man on long-term morphine has developed twitching and sedation that look like the drug itself has become the problem, and the fix everyone agrees on — switching to a different opioid — turns out to have no single correct starting dose.

A man who nearly died from a respiratory-depressant overdose needs a safer opioid, and the standard way of starting that safer drug requires him to go through real, deliberate withdrawal first — which is exactly the point a newer method is designed to avoid.

A woman who has tried and failed nearly every standard chronic-pain treatment is being considered for ketamine infusions, a therapy with real reported benefit and no settled protocol for exactly who should get it or how much.

A man already using cannabis on his own for chronic nerve pain wants his pain clinic to formally endorse and monitor it, and the honest answer sits between real, if modest, evidence of benefit and a genuine interaction risk with a drug he can't safely destabilize.

A woman whose fibromyalgia hasn't responded to any guideline-first-line drug wants to try low-dose naltrexone after reading about it online, and the real evidence behind it is genuinely promising and genuinely small.

A newly diagnosed patient needs a first fibromyalgia medication, and the honest answer is that the three FDA-approved options have never been tested directly against each other — the real decision has to be made on her own specific symptom picture instead.

A woman recently diagnosed with complex regional pain syndrome needs to start treatment while the condition is still in its most treatable early phase, and the three real evidence-backed options work through completely different mechanisms with no trial ever comparing them directly.

A man whose back pain never resolved after three surgeries is being considered for an implanted pump that delivers medication directly to his spinal fluid, and the device itself is the easier decision — what actually goes in it is not.

A man with both heart disease and kidney disease needs a long-term pain plan, and the two drug classes people usually reach for each carry a real risk pointed at one of his two vulnerable organs.

A woman on long-term opioids for chronic pain needs an acute pain plan after surgery, and the hospital's standard postoperative order set is built for a patient who has never taken an opioid before — not for her.

A man with radiating leg pain from a herniated disc is scheduled for an epidural steroid injection, and the specific steroid formulation chosen carries a real, if rare, risk of catastrophic spinal cord injury that a differently formulated version of the same drug class doesn't.

A woman is starting methadone for chronic pain for the first time, a drug whose real cost advantage comes bundled with a genuinely unpredictable pharmacokinetic profile and a cardiac risk that starting cautiously doesn't fully remove.

A woman with confirmed endometriosis has pelvic pain that hormonal suppression hasn't fully resolved, raising a real, uncomfortable possibility — that her pain may no longer be driven only by the disease the hormones are meant to control.